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ABSTRACT 1 
 2 
AIMS Association of elevated circulating levels of trimethylamine N-oxide (TMAO) with adverse 3 
outcomes in patients with heart failure (HF) has been described. However, response of TMAO 4 
levels to treatment and medications has not been investigated. Therefore, we investigated whether 5 
TMAO levels are responsive to guideline-recommended treatment and medications, and further 6 
reflect changes in outcomes. 7 
METHODS AND RESULTS TMAO levels were investigated in the systems BIOlogy Study to 8 
TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF), which addressed response to 9 
guideline-recommended pharmacological treatment. TMAO levels in 2,234 patients with new-10 
onset or progressively worsening HF showed strong associations with adverse events (mortality 11 
and /or rehospitalisation) at 1,2 and 3 years (HR 1.37–1.51, p≤0.019). Analysis of 972 patients 12 
with plasma available at both enrolment and follow-up visit showed reductions of B-type 13 
natriuretic peptide levels with guideline-based treatment (p<0.001), but not for TMAO levels. 14 
Moreover, patients with higher TMAO levels than median before and after treatment showed 15 
increased association with adverse outcomes (HR 2.21, 95% CI: 1.43-3.43, p<0.001) compared to 16 
patients with lower than median levels either before or after treatment (HR 1.13, 95% CI: 0.63-17 
2.04, p=0.684 and HR 1.14, 95% CI: 0.64-2.03, p=0.662, respectively).  18 
CONCLUSION TMAO levels were associated with adverse outcomes (mortality and/or 19 
rehospitalisation) in BIOSTAT-CHF, and did not respond to guideline-based pharmaceutical 20 
treatment in contrast to BNP levels which did as expected. Lower TMAO levels regardless of 21 
treatment were associated with favorable outcome.  22 
 23 
Key Words: Heart failure, gut microbiome, biomarker, metabolite, outcome study  24 
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INTRODUCTION 1 
  2 
The pathophysiology underlying heart failure (HF) is complex with multifaceted 3 
contributions of mechanical and neurohormonal factors and their collective effects on the heart.1 4 
Recently, the contribution of the gut microbiome to heart failure has been a topic of interest with 5 
the identification of the phosphatidylcholine metabolite, trimethylamine N-oxide (TMAO), to be a 6 
gut microbiota-derived molecule whose circulating levels when elevated are strongly associated 7 
with adverse outcomes for both acute2 and chronic HF3-7 as determined by cross-sectional studies.  8 
TMAO production involves gut microbiome-mediated processing of carnitine and/or choline (e.g. 9 
red meat and egg yolk as dietary sources) to the precursor trimethylamine (TMA) which is then 10 
converted to TMAO by flavin-containing monooxygenase 3 (FMO3) in the liver.8,9 TMAO cannot 11 
be produced effectively if the gut microbiome is absent (e.g. antibiotics) or the diet is 12 
vegan/vegetarian-based.10 Whether TMAO levels are responsive to medication and treatment, and 13 
further reflects changes in outcomes remains unknown. We hypothesized that TMAO levels would 14 
not respond to guideline directed medical therapy as conventional medications for HF do not target 15 
the gut microbiome.  16 
 The systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-17 
CHF) was a European multicentre, prospective, observational project involving 69 centres in 11 18 
countries11, designed to implement current European guidelines of HF treatment12 and to 19 
characterise biological pathways related to drug responsiveness to guideline-recommended 20 
pharmacological treatment for HF. 21 
 The present study investigated the association of circulating TMAO levels to outcomes in 22 
this contemporary European HF cohort with a particular focus on association of serial TMAO 23 
levels with treatment and outcomes.   24 
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METHODS 1 
 2 
Study Population 3 
BIOSTAT-CHF has been described in full elsewhere.11 In brief, the BIOSTAT-CHF cohort 4 
enrolled 2516 patients in total between 2010-2014 with progressive worsening or new-onset 5 
symptoms of HF, confirmed by either a left ventricular ejection fraction (EF) of ≤40% or plasma 6 
concentrations of B-type natriuretic peptide (BNP) and/or N-terminal pro-B-type natriuretic 7 
peptide (NT-proBNP) >400pg/ml or >2000pg/ml, respectively. The main aim of the project was to 8 
establish the effects of and response to initiation and up-titration of guideline-directed medical 9 
therapy, therefore all patients underwent treatment with furosemide ≥40mg/day or equivalent and 10 
received ≤50% of target doses of angiotensin-converting-enzyme inhibitors or angiotensin II 11 
receptors (ACEi/ARBs) and beta-blockers at time of study entry. Each patient consented (written 12 
and informed) to have blood samples taken and outcomes surveyed. The study complied with the 13 
Declaration of Helsinki and was approved by the local ethics committee. 14 
 15 
Sample Collection 16 
Blood samples were collected at the initial enrolment visit (V1) in all patients and at a 17 
follow-up visit (V2) at approximately nine months in possible patients.  18 
 19 
Biomarker Measurements 20 
Plasma was aliquoted and stored at -80 ºC until analysis. At the time of analysis, samples 21 
were defrosted at room temperature and analysed immediately. TMAO levels were measured in 22 
plasma samples using stable isotope dilution [d9-(trimethyl)-labelled TMAO] followed by ultra-23 
performance liquid chromatography-tandem mass spectrometry on a Quattro Premier XE triple 24 
quadrupole mass spectrometer (Waters Corp., Milford, MA, USA), using conditions described 25 
previously with a coefficient of variation of 5.7% for measurements throughout the study. 2,13 All 26 
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further clinical biomarkers were measured either at local hospital site or within the BIOSTAT-1 
CHF central laboratory.11 BNP was measured using Luminex multiplexed bead-based 2 
immunoassays at Alere (San Diego, California).   3 
 4 
Endpoints 5 
The primary outcome was all-cause mortality (mortality), with a secondary outcome 6 
measure as the composite event of mortality combined with rehospitalisation due to HF 7 
(mortality/HF). End points were obtained as previously reported for the BIOSTAT-CHF 8 
protocol.11 9 
 10 
Statistical Analyses 11 
Investigations were performed on a non-imputed BIOSTAT-CHF database and 12 
modifications were made where sufficient data were not available. For patients that completed a 13 
second visit, changes in demographics from initial enrolment visit (V1) to the follow-up visit (V2) 14 
were compared using Wilcoxon matched-pair signed-rank test for continuous variables and the 15 
McNemar test for categorical variables. Cumulative incidences of events were investigated using 16 
Kaplan-Meier survival curves for tertiles of TMAO at baseline and compared using the Mantel-17 
Cox log rank test. Cox proportional hazards regression analyses were performed to investigate 18 
association of plasma TMAO levels with outcomes in both a univariable and multivariable 19 
manner. 20 
 Multivariable adjustments were made using the previously defined BIOSTAT-CHF 21 
compact and extended risk models.14  22 
To investigate the implications of serial changes in plasma TMAO levels with treatment on 23 
outcomes, patients with data available for both V1 and V2 were further classified according to 24 
respective TMAO levels at each time point. In total, four groups were created and classified by 25 
low or high TMAO levels (according to the median) for each visit. Cox proportional hazards 26 
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regression analysis was performed to investigate the change in associations with outcomes across 1 
groupings, with low V1 and low V2 (L/L group) deemed as the reference value. Similar analysis 2 
was done with natriuretic peptide levels. Decision tree analysis was performed using χ2 automatic 3 
interaction detection (CHAID) and resultant groupings tested for association with outcomes using 4 
Cox proportional hazards regression and Kaplan-Meier survival curves. 5 
Statistical analyses were performed using IBM SPSS Statistics (v24, IBM, Armonk, NY, 6 
USA). A P-value of <0.05 was considered statistically significant.  7 
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RESULTS 1 
 2 
Study Population 3 
Plasma TMAO levels were determined in 2234 patients (88.8%) with available baseline 4 
plasma samples of the 2516 patients that were included in BIOSTAT-CHF. 5 
Patient demographics are shown in Table 1. The cohort consisted of 2234 patients with an 6 
age of 70 [61–78] years (median [interquartile range]) with 74% being male and 32% with history 7 
of previous HF hospitalisation. Patients were predominantly New York Heart Association 8 
(NYHA) functional classification of HF classes II and III (combined 86%), and presented with HF 9 
with reduced ejection fraction (EF) in 81%.  10 
Patient characteristics according to TMAO median and tertiles are shown in 11 
Supplementary Table S1. Patients with higher TMAO levels at baseline had more comorbidities, 12 
advanced heart failure and worsened renal function as well as less use of ACEi/ARB and 13 
mineralocorticoid receptor antagonist (MRA). 14 
972 out of the 2234 patients were analysed at follow up for TMAO levels (320 patients 15 
died before 9 months follow-up resulting in 1914 patients remaining of whom samples were 16 
available in 972 patients).  17 
This subset of 972 patients had undergone guideline-based treatment for HF and showed 18 
improvement in clinical variables (Table 1) as shown by reduction of congestion and peripheral 19 
oedema (-38% and -27%, p<0.001), reduction in BNP levels (from 206 [86-408] pg/mL to 132 20 
[51-327] pg/mL, p<0.001), reduction in NYHA class (e.g. 48% to 24% for NYHA class III) and 21 
improvement of EF (30% [25-35] to 35% [28-42], p<0.001). Use of beta-blocker, ACEi/ARBs and 22 
MRA were increased (85% to 93%, 74% to 89%, and 52% to 59% respectively, all p<0.001), and 23 
use of diuretics was reduced (100% to 94%, p<0.001) between V1 and V2.  24 
Differences in characteristics between patients with and without TMAO measurements at 25 
V1 and V2 are shown in Supplementary Table S2. More males were in the group with TMAO 26 
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measured as compared to those not measured at V1, and those not measured at V2 showed lower 1 
use of beta-blockers and ACEi/ARBs, and lower eGFR levels. 2 
 3 
Association of Circulating TMAO Levels with Adverse Outcomes 4 
During the 3-year observation period, there were 591 mortality events (26.5%) and 909 5 
composite events of mortality/HF (40.7%).  To understand the association of baseline plasma 6 
TMAO levels and outcomes, Kaplan-Meier survival analyses were performed across TMAO 7 
tertiles (tertile1=<4.2 µmol/L; tertile2=4.2-8.4 µmol/L; tertile3=>8.4 µmol/L). Patients with 8 
elevated TMAO levels were associated with more deaths and composite events during the 9 
observation period, with a graded increase in the cumulative incidence of events with increasing 10 
TMAO levels (p<0.001, Figure 1).  11 
To investigate the association of TMAO levels with outcomes, log TMAO levels were 12 
added to the previously described BIOSTAT-CHF compact and extended risk models for mortality 13 
and mortality/HF at 1, 2 and 3 years (11) (Table 2). The BIOSTAT-CHF compact risk model for 14 
mortality included age, haemoglobin, blood urea, log BNP and use of beta-blocker at baseline. 15 
BNP levels were substituted for NT-proBNP due to insufficient availability of data (data available 16 
in only 47% patients for NT-proBNP). When adjusted for this model, TMAO levels were 17 
associated with mortality and mortality/HF at 1, 2 and 3 years (HR 1.37-1.51, p≤0.019). The 18 
BIOSTAT-CHF extended risk model for mortality included ischaemic aetiology, previous chronic 19 
obstructive pulmonary disease, diastolic blood pressure (BP) and sodium in addition to variables 20 
previously described for the compact model of mortality. When adjustment using this model was 21 
performed, TMAO remained an independent predictor of outcome for mortality at all time points 22 
(HR 1.40-1.44, p≤0.030) (see Table 2 for detailed statistical results). The BIOSTAT-CHF 23 
compact risk model for mortality/HF included age, previous HF hospitalisation, peripheral 24 
oedema, systolic blood pressure, log BNP, haemoglobin, sodium and use of beta-blocker at 25 
baseline. High-density lipoprotein data were excluded due to availability in only 1036 patients 26 
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(46%). TMAO levels were associated with mortality/HF at all time points (p≤0.019). Finally, the 1 
BIOSTAT-CHF extended risk model for mortality/HF included current smoking, previous chronic 2 
obstructive pulmonary disease and estimated glomerular filtration rate (eGFR) in addition to the 3 
variables of the compact model. Presence of raised jugular vein dilatation was excluded due to low 4 
availability (69%).  However, in this model, TMAO was not able to independently predict 5 
mortality/HF at any time point (p≥0.054). Therefore, TMAO levels showed added value to risk 6 
models for association with mortality outcome and mortality/HF at 1, 2 and 3 years, except for the 7 
extended model for mortality/HF. Associations of TMAO on outcome were not affected when 8 
adjusted for body mass index (BMI) on mortality and mortality/HF, except for the extended model 9 
of mortality/HF (Supplementary Table S3). 10 
When TMAO was added to the BIOSTAT-CHF compact and extended models for 11 
mortality at 2 years, there were only marginal gains in C-statistics (compact model with vs without 12 
TMAO = 0.710 vs 0.705, p=0.138; extended model with vs without TMAO = 0.728 vs 0.723, 13 
p=0.073) (Supplementary Table S4). However, net reclassification index (NRI) [16.8 (95%CI: 14 
6.6-27.1), p=0.001, 13.4 (3.0-23.9), p=0.012, respectively] and integrated discrimination 15 
improvement (IDI) analyses [0.5 (0.2-0.9), p=0.004, 0.5 (0.2-0.8), p=0.004, respectively] 16 
demonstrated the added value of TMAO (Supplementary Table S4). To note, reclassification 17 
analysis is known to offer greater sensitivity in highlighting improvement for the inclusion of an 18 
additional variable in comparison to C-statistic analysis15. 19 
In patients with EF<40% (n=1619), TMAO levels showed added value to BIOSTAT-CHF 20 
risk models for association with mortality outcome and mortality/HF at 1, 2 and 3 years, except for 21 
the extended model for mortality/HF at 1 year (HR≥1.27, p≤0.041, see Supplementary Table S5 22 
for detailed statistical results).  However, this association was not seen in patients with EF≥40%.  23 
BIOSTAT-CHF did not assess echocardiographic parameters beyond EF as needed for 24 
classification of HF phenotype (e.g. HFrEF, HFpEF), therefore effects of HF phenotype could not 25 
be further investigated. 26 
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Association of Serial Changes in TMAO Levels with Adverse Outcomes 1 
To understand the associations of subsequent adverse outcomes with serial changes in 2 
circulating TMAO levels following treatment, TMAO levels at enrolment (V1) and at the follow-3 
up (V2) time point at nine months after treatment were split into high and low level groups (in 4 
relation to median values; V1 median, 5.7 µmol/L; V2 median, 6.6 µmol/L). The groups were 5 
comprised of low V1 and low V2 (L/L, n=315), low V1 and high V2 (L/H, n=171), high V1 and 6 
low V2 (H/L, n=171), and high V1 and high V2 (H/H, n=315) levels. Analysis showed that 7 
patients with low TMAO levels at V1 with high levels at V2 (L/H) and those who showed high 8 
levels at V1 with low levels at V2 (H/L) did not show an increased association with mortality at 2 9 
years following the follow-up visit as compared to the reference L/L group [HR (95% confidence 10 
intervals); 1.13 (0.63-2.04) and 1.14 (0.64-2.03) for L/H and H/L, respectively]. However, patients 11 
who showed high TMAO levels at both time points (H/H) showed increased association with 12 
mortality at 2 years after the follow-up visit [HR 2.21 (1.43-3.43), p<0.001] (Figure 2A). Thus, 13 
increased association with mortality was seen in patients with sustained increases in TMAO levels 14 
at both enrolment and follow-up, or conversely, increased association was not seen in patients that 15 
exhibited low TMAO levels at either visit. 16 
Similar analysis was done with natriuretic peptide levels (Figure 2C). Patients were 17 
divided into four groups by median BNP levels for V1 and V2 (V1 median, 206 pg/mL; V2 18 
median, 132 pg/mL). This produced groups of 297, 148, 148, and 297 patients for L/L, L/H, H/L, 19 
and H/H groups, respectively. Patients who showed low BNP levels following an initially high 20 
level (H/L) showed a similar association with mortality (HR 1.17 (0.55-2.48), p=0.679) as 21 
compared to the L/L group. Patients with high levels of BNP at V2 (L/H and H/H) showed 22 
increased association with mortality at 2 years [L/H HR 2.70 (1.45-4.99), p=0.002; H/H HR 3.56 23 
(2.11-6.00), p<0.001]. Thus, natriuretic peptide showed a different trend where low natriuretic 24 
peptide levels after treatment at follow-up were associated with better outcomes, and high levels at 25 
follow-up were associated with worse outcomes regardless of initial levels.  26 
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To note, these associations were also seen when adjusted for renal function (Figures 2B, 1 
D). Changes in TMAO were associated with mortality even when adjusted for potential 2 
confounders such as BMI, systolic BP, EF and renal function (eGFR) (Supplementary Table S6).  3 
These associations were also seen when patients were divided into tertiles (high/mid/low 4 
TMAO levels) at V1 and V2 instead of using median levels to split into high/low groups 5 
(Supplementary Figure S1). Tertile analysis showed that high to high, mid to high, and high to 6 
mid level changes showed association with adverse outcome consistent with those of sustained 7 
high levels from V1 to V2 using median analysis thus confirming that sustained high levels of 8 
TMAO are associated with adverse outcome. 9 
Analysis was also done in patients with EF<40% (n=713) (supplementary Table S7). 10 
Association with mortality was seen in patients with sustained increases in TMAO levels at both 11 
V1 and V2 even after adjustment for potential confounders (BMI, systolic BP, EF and eGFR). 12 
 13 
Decision Tree Analysis 14 
 Decision tree analysis was done to investigate TMAO levels at V1 and V2 as risk 15 
stratification biomarkers for mortality at 2 years following V2 (Figure 3A). This showed that 16 
stratifying patients by median TMAO levels at V1 and V2 generated three groups of risk that 17 
confirmed associations reported by the previous Cox proportional hazards regression analysis. 18 
Those with TMAO levels below the median at V1 (group A) showed a similar level of risk to 19 
those who initially presented with high levels that subsequently showed low levels (group B); 20 
relative risks (RR) of groups A and B were 10.7% and 12.5%, respectively. Conversely, those who 21 
presented with and maintained high levels of circulating TMAO (group C) showed an increased 22 
level of risk (RR of 26.0%; and HR 2.10 (1.44-3.06), p<0.001 compared to group A). Kaplan-23 
Meier survival analysis confirmed that group C had an increased number of cumulative events 24 
compared to groups A and B (log-rank p<0.001, Figure 3A inset). 25 
13 
 
 Similar analysis was also done on natriuretic peptide levels (Figure 3B). Decision tree 1 
analysis showed that a high level of BNP at V2 (>132 pg/mL) was associated with worse 2 
prognosis irrespective of measurement levels at the initial visit. Patients who had low BNP levels 3 
at V2 (groups A and C) showed the lowest level of risk (RR of 6.5% and 8.0% for groups A and C, 4 
respectively), and those with high levels at V2 (groups B and D) showing increased levels of risk 5 
(group RR of 18.4% and 26.7% for groups B and D, respectively). Kaplan-Meier survival analysis 6 
confirmed similar levels of cumulative events for groups A and C, and increase in events for 7 
groups B and D (log-rank p<0.001, Figure 3B inset). These results showed effects of TMAO on 8 
predictive values by cut-off levels at both V1 and V2, and therefore highlighted the importance of 9 
serial measurements. 10 
 11 
Response of Circulating TMAO Levels to Treatment and Association with Outcomes  12 
 Response of TMAO levels to treatment was also investigated (Table 3) as BIOSTAT-CHF 13 
had also recorded dosage titrations. We hypothesized that TMAO levels would not respond to 14 
guideline directed medical therapy as conventional medications for treatment of HF do not target 15 
the gut microbiome in contrast to BNP, the comparator and reference, which is known to respond 16 
to treatment with lower levels16.  For patients using ACEi/ARBs, regardless of whether they had 17 
achieved optimal titration to recommended dosage or not, TMAO levels showed increases by V2. 18 
Beta-blocker use showed increases in TMAO when less than 50% optimal dosage was used but 19 
not when higher levels of optimization were achieved. When combined for these drugs, less than 20 
50% optimal titration showed increase in TMAO levels but not when higher levels of titration 21 
were achieved. In contrast, BNP showed reduced levels when greater than 50% optimal titration of 22 
either or both ACEi/ARBs and/or beta-blocker were used, but not when less than 50% optimal 23 
titration was achieved. TMAO levels were not responsive to optimized current guideline-based HF 24 
treatment in contrast to BNP levels. 25 
14 
 
 In patients with EF<40%, TMAO levels showed increases regardless of optimization of 1 
ACEi/ARBs, and those on beta-blockers did not show significant difference in patients with 2 
greater than 50% optimal titration but showed significant increase in those with less than 50% 3 
optimal titration (Supplementary Table S8). 4 
 Titration of ACEi/ARBs, beta-blockers or both did not show interaction with TMAO levels 5 
on effects on mortality (ACEi/ARBs, beta-blockers or both; Pinteraction =1.00, Pinteraction =0.242 and 6 
Pinteraction=0.442, respectively).  7 
15 
 
DISCUSSION 1 
 2 
 The present analysis of BIOSTAT-CHF validates that initial TMAO levels are associated 3 
with adverse outcomes (mortality and mortality/HF). In contrast to natriuretic peptides which 4 
responded to treatment as expected, TMAO did not respond to guideline medical treatment. 5 
Patients with sustained higher levels of TMAO before and after treatment were associated with 6 
worse outcomes, and patients with lower levels either before or after treatment did not show 7 
additional risk. 8 
 9 
Comparison to Previous Studies 10 
The present study investigated the role of the gut microbiome-derived metabolite 11 
biomarker of HF, TMAO, in the BIOSTAT-CHF cohort. As compared to previous acute and 12 
chronic HF patient cohorts in which TMAO levels have been investigated2-7, the BIOSTAT-CHF 13 
cohort included over 2000 patients with progressive worsening or new-onset symptoms of HF. In 14 
the present cohort, increased TMAO levels were independently associated with adverse outcomes 15 
of mortality and a composite endpoint of mortality and hospitalization due to HF. Taken together 16 
with past observations in acute and chronic HF cohorts2-7, elevated TMAO levels are consistently 17 
associated with adverse outcomes in patients with HF (mortality and/or HF rehospitalisation).  18 
 19 
Novel Findings from the Present Study 20 
 One of the main aims of BIOSTAT-CHF was to establish the effects of response to 21 
initiation and up-titration of guideline-directed medical therapy in HF patients.11 Drug therapy at 22 
enrolment, changes in the use of medications and up-titration to doses were recorded allowing for 23 
analysis of TMAO levels over time in response to and association with outcomes after treatment 24 
which were the first to our knowledge. Further, as natriuretic peptide levels (BNP/ NT-proBNP) 25 
were included in the entry criteria of BIOSTAT-CHF, comparison of temporal characteristics with 26 
16 
 
natriuretic peptide levels was also possible in the present study. To note, all patients in BIOSTAT-1 
CHF underwent treatment with furosemide ≥40mg/day or equivalent and received ≤50% of target 2 
doses of ACEi/ARBs and beta-blockers at time of enrolment which were then up-titrated in the 3 
next three months. 4 
 The initial finding of interest was that a low TMAO level (as compared to median) either at 5 
baseline or at follow-up was sufficient to confer better outcomes as compared to patients that 6 
showed sustained high levels at both initial and follow-up time-points. This was in contrast to 7 
natriuretic peptide levels, which showed only better outcomes when there were low levels at 8 
follow-up as consistent with previous studies which have shown that lower levels of natriuretic 9 
peptide with treatment are associated with favourable outcomes.16 Another finding of interest was 10 
that current guideline-based HF treatment did not affect TMAO levels. In fact, reduction in TMAO 11 
levels were not observed in patients with titration of dosages to greater than 50% of the 12 
recommended dosage, and a significant increase in TMAO levels was seen in patients achieving 13 
less than 50% optimal titration of either ACEi/ARBs or beta-blockers. In contrast, natriuretic 14 
peptide levels showed a decrease in response to optimal up-titration (>50%) of ACEi/ARBs and/or 15 
beta-blockers as consistent with previous reports that have addressed effects of HF treatment on 16 
natriuretic peptide levels.17,18 17 
On added value of TMAO levels to risk prediction, TMAO added to risk stratification of 18 
the BIOSTAT-CHF risk models (compact and extended) for mortality and mortality/HF at 1, 2 and 19 
3 years, with the exception of the extended model for mortality/HF.  20 
 21 
Clinical Implications of all the Available Evidence 22 
Our findings showed that current guideline-based pharmacological treatment in HF 23 
impacted natriuretic peptide levels as expected but did not reduce TMAO levels. Studies have 24 
shown that dietary modulation (e.g. vegan/vegetarian-based) as well as drugs (e.g. antibiotics, 25 
17 
 
small compounds) in addition to natural inhibitors (e.g. 3,3-dimethyl-1-butanol, DMB) may lower 1 
TMAO levels19.  2 
Therapeutic intervention to the gut microbiome/dysbiosis and/or intestinal permeability 3 
might be potential additive treatments for HF. However, TMAO lowering has yet to be shown to 4 
improve outcomes of heart disease and will be a topic for future investigation. 5 
 6 
Mechanistic Implications 7 
Although the mechanisms contributing to the increase of TMAO in the setting of HF are 8 
likely multifactorial, some plausible mechanisms focused on effects of intestinal dysfunction on 9 
increased TMAO include; 1)  increased congestion and intestinal dysfunction/congestion in HF 10 
leading to dysbiosis of the gut microbiome20, and 2) congestion leading to increased intestinal 11 
permeability21 resulting in increased entry of the precursor TMA into intestinal blood flow then 12 
into the circulation. 13 
 14 
Study Limitations  15 
BIOSTAT-CHF was an observational study, therefore optimisation and dosages were 16 
decided by clinical discretion.  Although there is strong evidence that high blood levels of TMAO 17 
correlate with cardiovascular events,2-7 there remains possibility that increased concentration of 18 
TMAO in patients with increased cardiovascular risk may be not a causative relationship. Other 19 
potential limitations are that we did not have any information regarding baseline diet, physical 20 
activity level and change in weight to adjust for these confounding factors. There is potential for 21 
residual measured and/or unmeasured confounding factors to influence association of TMAO with 22 
outcomes. Circulating TMAO levels likely depend on a multitude of factors including diet, gut 23 
microbiota composition and activity, permeability of the gut-blood barrier, activity of liver 24 
enzymes, rate of methylamine excretion, and effects of medications.22    25 
18 
 
CONCLUSION 1 
 2 
 TMAO levels were able to add to risk stratification of HF in the BIOSTAT-CHF cohort. 3 
Elevated levels of circulating TMAO were associated with adverse outcomes (mortality and/or HF 4 
hospitalisation) and added to the clinical BIOSTAT-CHF risk models. Serial analysis of TMAO 5 
levels with treatment showed that patients with sustained higher levels of TMAO before and after 6 
treatment were associated with worse outcomes, and that low levels either at baseline or at follow-7 
up were sufficient for association with better outcomes.   8 
19 
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 2 
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Table 1. Patient characteristics. 
 Total cohort 
(n=2234) 
Patients with follow-up visit (n=972) 
 Visit 1 Visit 2 p value 
TMAO (µmol/L) 5.9 [3.6-10.8] 5.7 [3.5-9.9] 6.6 [3.7-11.1] <0.001 
Demographics     
Age 70 [61-78] 69 [61-78]   
Male 1654 (74%) 727 (75%)   
Body mass index (kg/m2)  27.2 [24.2-30.8] 27.2 [24.4-30.9] 27.3 [24.3-30.9] 0.850 
Current smoker 312 (14%) 129 (13%)   
Ischemic aetiology 1214 (55%) 524 (54%)   
Hypertension 1401 (63%) 613 (63%)   
Diabetes mellitus 730 (33%) 306 (32%)   
COPD 387 (17%) 172 (18%)   
Previous HF hospitalisation 703 (32%) 292 (30%)   
NYHA class    I 52 (2%) 27 (3%) 148 (16%) 
<0.001 
                            II 768 (35%) 381 (40%) 572 (60%) 
                            III 1088 (50%) 451 (48%) 224 (24%) 
                            IV 260 (12%) 89 (9%) 11 (1%) 
LVEF (%) 30 [25-36] 30 [25-35] 35 [28-42] <0.001 
HFrEF (EF<40%) 1619 (81%) 713 (83%)   
Clinical signs     
Pulmonary congestion 1149 (52%) 463 (49%) 92 (11%) <0.001 
Peripheral oedema 1103 (59%) 372 (52%) 175 (25%) <0.001 
Systolic blood pressure (mmHg) 120 [110-139] 123 [110-140] 122 [110-140] 0.409 
Diastolic blood pressure (mmHg) 74 [66-82] 75 [67-85] 75 [65-80] 0.002 
Heart rate (beat/min) 76 [67-90] 75 [65-89] 70 [61-80] <0.001 
Medication     
  Beta-blocker 1863 (83%) 825 (85%) 906 (93%) <0.001 
  ACE inhibitor or ARB 1638 (73%) 720 (74%) 862 (89%) <0.001 
  MRA 1193 (53%) 509 (52%) 572 (59%) <0.001 
  Diuretics 2232 (100%) 971 (100%) 971 (94%) <0.001 
Laboratory      
  Haemoglobin (g/dL) 13.3 [11.9-14.5] 13.4 [12.1-14.6] 13.3 [12.0-14.3] 0.013 
  BNP (pg/mL) 231 [92-475] 206 [86-408] 132 [51-327] <0.001 
  Urea (mmol/L) 11.1 [7.4-17.9] 9.2 [6.7-14.5] 10.2 [7.0-16.0] <0.001 
  eGFR* (ml/min/1.73m2) 62 [48-79] 64 [48-81] 60 [45-78] <0.001 
  Sodium (mmol/L) 140 [137-142] 140 [137-142] 139 [137-141] 0.207 
 
Table1
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Data are presented as median [interquartile range] for continuous variables or n (%) for 
categorical values. P values are quoted for Wilcoxon matched-pair signed-rank tests for 
continuous variables and McNemar tests for categorical variables. *Estimated by CKD-
EPI formula. ACE=angiotensin-converting enzyme; ARB=angiotensin receptor blocker; 
BNP=B-type natriuretic peptide; COPD=chronic obstructive pulmonary disease; 
eGFR=estimated glomerular filtration rate; HF=heart failure; HFrEF=heart failure with 
reduced ejection fraction; LVEF=left ventricular ejection fraction; 
MRA=mineralocorticoid receptor antagonist; NYHA=New York Heart Association; 
TMAO=trimethylamine-N-oxide.  
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ox proportional hazards regression analyses for association of baseline plasm
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 levels and outcom
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F cohort.  
    
Unadjusted 
 
Adding TM
AO to 
Compact model 
 
Adding TM
AO to 
Extended model 
 
 
 
 
 
 
H
R
 (95%
 C
I) 
p value 
 
H
R
 (95%
 C
I) 
p value 
 
H
R
 (95%
 C
I) 
p value 
M
ortality 
 
 
 
 
 
 
 
 
1 year 
2.43 (1.93-3.05) 
<0.001 
 
1.51 (1.14-2.00) 
0.004 
 
1.40 (1.03-1.89) 
0.030 
2 years 
2.29 (1.90-2.77) 
<0.001 
 
1.49 (1.18-1.88) 
0.001 
 
1.44 (1.12-1.84) 
0.004 
3 years 
2.27 (1.90-2.72) 
<0.001 
 
1.47 (1.18-1.84) 
0.001 
 
1.42 (1.13-1.80) 
0.003 
M
ortality/HF 
 
 
 
 
 
 
 
 
1 year 
1.92 (1.61-2.28) 
<0.001 
 
1.42 (1.06-1.90) 
0.019 
 
1.12 (0.90-1.40) 
0.281 
2 years 
1.91 (1.64-2.22) 
<0.001 
 
1.39 (1.09-1.76) 
0.007 
 
1.19 (0.98-1.45) 
0.077 
3 years 
1.93 (1.66-2.23) 
<0.001 
 
1.37 (1.09-1.72) 
0.007 
 
1.21 (1.00-1.46) 
0.054 
 C
om
pact m
odel for all-cause m
ortality (m
ortality): age, blood urea (log-transform
ed), B
N
P (log-transform
ed), haem
oglobin and use of 
beta-blocker at baseline. C
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pact m
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ortality or rehospitalisation due to heart failure (m
ortality/H
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a, systolic blood pressure, B
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P (log-transform
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 and use of beta-blocker at 
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, diastolic blood pressure and sodium
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ortality/H
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O
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R
) and 95%
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-type natriuretic peptide; C
O
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=chronic obstructive pulm
onary disease; eG
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erular 
filtration rate; H
F=heart failure; TM
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 Table 3. R
esponse of TM
A
O
 and B
N
P levels to guideline-based treatm
ent (less than 50%
 or not of optim
al recom
m
ended dosage). 
  
 
TM
AO (n=972) 
 
BNP (n=890) 
Dose up-titration 
V
1 (µm
ol/L) 
V
2 (µm
ol/L) 
p value* 
 
V
1 (pg/m
L) 
V
2 (pg/m
L) 
p value* 
ACEi/ARBs 
 
 
 
 
 
 
 
  <50%
 
6.3 [3.8-11.8] 
7.1 [3.9-12.9] 
0.002 
 
237 [104-469] 
172 [70-420] 
0.122 
  ≥
50%
 
5.2 [3.4-8.9] 
6.2 [3.5-10.3] 
0.002 
 
171 [77-342] 
108 [39-259] 
<0.001 
Beta-blocker 
 
 
 
 
 
 
 
  <50%
 
5.6 [3.5-9.2] 
6.7 [3.7-11.2] 
<0.001 
 
183 [85-392] 
141 [55-369] 
0.159 
  ≥
50%
 
5.7 [3.7-10.5] 
6.5 [3.7-10.8] 
0.084 
 
222 [89-434] 
126 [44-277] 
<0.001 
Both drugs 
 
 
 
 
 
 
 
  Either <50%
 
5.7 [3.5-9.7] 
6.7 [3.7-11.9] 
<0.001 
 
203 [86-411] 
140 [56-366] 
0.053 
  B
oth ≥
50%
 
5.6 [3.6-10.1] 
6.5 [3.6-10.5] 
0.284 
 
208 [88-389] 
113 [37-244] 
<0.001 
 p value; initial enrolm
ent visit (V
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ilcoxon m
atched-pair signed-rank test. 
A
C
Ei=angiotensin-converting enzym
e inhibitor; A
R
B
=angiotensin receptor blocker; B
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-type natriuretic peptide; 
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FIGURE LEGENDS 
 
Figure 1. Cumulative incidence of events across TMAO tertiles.  
A: Cumulative incidence plot for all-cause mortality (mortality) at 3 years stratified by TMAO 
tertiles. B: Cumulative incidence plot of mortality and/or rehospitalisation due to heart failure 
(mortality/HF) at 3 years stratified by TMAO tertiles. Number of events are shown below. 
 
Figure 2. Forest plot showing the association with outcome for patients with TMAO (top) 
and BNP (bottom) levels measured at baseline and secondary visit. 
Patients were divided into four groups according to TMAO (top) and BNP (bottom) concentrations 
at the initial enrolment visit (V1) and follow-up visit (V2) relative to the median of each visit point 
(TMAO; 5.7 µmol/L and 6.6 µmol/L, BNP; 206 pg/mL and 132 pg/mL, for V1 and V2 
repsectively). H/H=high V1 and high V2; H/L=high V1 and low V2; L/H=low V1 and high V2; 
L/L=low V1 and low V2. Cox proportional hazards regression modelling was used to compare the 
risk of mortality at 2 years after V2 among the four groups of patients using L/L as the reference 
on each occasion (A and C unadjusted, B and D adjusted with renal function (eGFR at V1) for 
TMAO and BNP respectively). Data are presented as hazard ratio (HR) and 95% confidence 
interval (CI). BNP=B-type natriuretic peptide; eGFR=estimated glomerular filtration rate; 
TMAO=trimethylamine-N-oxide. 
 
Figure 3. Classification tree to show risk stratification for mortality at 2 years using 
combined measurements at baseline and secondary visit for TMAO (top) and BNP (bottom). 
A: Classification tree using plasma TMAO level at the initial enrolment visit (V1) as the initial 
classifier, followed by plasma TMAO level at follow-up visit (V2) enables effective selection of 
low- and high-risk groups of patients (main body) and increased cumulative event risk in Group C 
compared to Groups A and B (inset). B: Classification tree using plasma BNP level at V1 as the 
Figure Legends Click here to access/download;Figure;Figure legends.docx
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initial classifier, followed by plasma BNP level at V2 enables effective selection of low- and high-
risk groups of patients (main body) and increased cumulative event risk in Groups B and D 
compared to A and C (inset). Data are presented as hazard ratio (HR) and 95% confidence interval 
(CI). Number of events are shown below. BNP=brain natriuretic peptide; TMAO=trimethylamine-
N-oxide. 
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